Digoxin Use and Subsequent Clinical Outcomes in Patients With Atrial Fibrillation With or Without Heart Failure in the ENGAGE AF‐TIMI 48 Trial

Author:

Eisen Alon12,Ruff Christian T.12,Braunwald Eugene12,Hamershock Rose A.12,Lewis Basil S.3,Hassager Christian4,Chao Tze‐Fan5,Le Heuzey Jean Yves6,Mercuri Michele7,Rutman Howard7,Antman Elliott M.12,Giugliano Robert P.12

Affiliation:

1. TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA

2. Department of Medicine, Harvard Medical School, Boston, MA

3. Lady Davis Carmel Medical Center, Haifa, Israel

4. Rigshospitalet, Copenhagen, Denmark

5. Taipei Veterans General Hospital, Taipei, Taiwan

6. Georges Pompidou Hospital, René Descartes University, Paris, France

7. Daiichi‐Sankyo, Parsippany, NJ

Abstract

Background Digoxin is widely used in patients with atrial fibrillation despite the lack of randomized controlled trials. Observational studies report conflicting results regarding its association with mortality, perhaps because of residual confounding by the presence of heart failure ( HF ). Methods and Results In the ENGAGE AFTIMI 48 (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation‐Thrombolysis in Myocardial Infarction 48) trial, clinical outcomes of patients with atrial fibrillation with and without HF were examined by baseline digoxin use during a median follow‐up of 2.8 years. HF was defined at baseline as prior or current clinical stage C or D HF . Of 21 105 patients enrolled, 6327 (30%) were treated with digoxin at baseline. Among patients without HF (n=8981), digoxin use (20%) was independently associated with sudden cardiac death (adjusted hazard ratio, 1.51; 95% CI, 1.10–2.08), with no significant interaction by age, sex, left ventricular ejection fraction, renal function, or concomitant medications ( P >0.05 for each). Consistent results were observed using propensity matching (adjusted hazard ratio for sudden cardiac death, 1.90; 95% CI , 1.36–2.65). Among patients with HF (n=12 124), digoxin use (37%) was associated with an increase in all‐cause death, cardiovascular death, sudden cardiac death, and death caused by HF /cardiogenic shock ( P <0.01 for each), but not with noncardiovascular death, stroke/systemic embolism, or myocardial infarction. Conclusions In this observational analysis of patients with atrial fibrillation without investigator‐reported HF , digoxin use was significantly associated with sudden cardiac death. While residual confounding cannot be excluded, the association between digoxin use and worse clinical outcomes highlights the need to examine digoxin use, particularly when prescribed to control heart rate in patients with atrial fibrillation in a randomized trial. Clinical Trial Registration URL : http://www.clinicaltrials.gov . Unique identifier: NCT 00781391.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cardiology and Cardiovascular Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3